Basically, what a hospital needs to accomplish is to eliminate spots on the CT scan image that are "less important" -- meaning, in this application, spots that don't reflect the actual image of the lungs. That can be done through a common algorithm called singular value decomposition (SVD). To apply the SVD, a little preprocessing is necessary. A CT scan image is normally represented in three dimensions. One dimension is a series of "slices," each slice being a two-dimensional image. The SVD algorithm requires a two-dimensional matrix, but it's easy to reduce three dimensions to two: just string out the rows of each two-dimensional matrix, as you might unfold a fold-up walking stick or measuring stick. The SVD algorithm produces a new set of matrices with powerful properties.

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2. "There is an urgent need to identify effective drugs that treat or prevent COVID-19," said Anandasankar Ray, a professor of molecular, cell, and systems biology who led the research. "We have developed a drug discovery pipeline that identified several candidates." The drug discovery pipeline is a type of computational strategy linked to artificial intelligence -- a computer algorithm that learns to predict activity through trial and error, improving over time. With no clear end in sight, the COVID-19 pandemic has disrupted lives, strained health care systems, and weakened economies.

AI could also have a transformative effect on clinical decision-making through the utilisation of the huge levels of genomic, biomarker, phenotype, behavioural, biographical and clinical data that is generated across the health system. Bayer and Merck & Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form of pulmonary hypertension. The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and efficiently. The CTEPH Pattern Recognition Artificial Intelligence obtained FDA Breakthrough Device Designation in December 2018.

… mention of CAs in the US Food and Drug Administration’s (FDA) proposed regulatory framework for AI or machine learning for software as a medical …

Artificial Intelligence has come into everyone's life in one way or another over the past decade. One of the fastest growing areas using this new technology is the healthcare industry. There have been many advancements over the years and new ways of using it coming out every day. These advancements have even come into light with physicians using data they receive from wearables like smartwatches. Companies like Microsoft and Apple have entire teams dedicated to healthcare.

Zebra Medical Vision, an Israeli medical imaging analytics company, said on Monday it received clearance from the U.S. Food and Drug Administration for its mammography technology. The company's latest cleared product uses artificial intelligence to prioritize and identify suspicious mammograms. The mammograms are automatically sent to Zebra's platform, where they are processed and analysed for suspected breast lesions. The HealthMammo product then returns its result to the radiologist. It is the company's first oncology tool to receive FDA clearance.

On June 18, the Food and Drug Administration authorized the use of pooled testing for identifying COVID-19 infections. The method allows up to four swabs to be tested at once – a strategy that is expected to greatly expand frequent testing to larger sections of the population. The idea is that if a bundled sample comes back positive, then all the individuals in that sample will need to be tested separately. If a bundled sample comes back clean, however, that's four people who don't need to be tested further, saving public health officials time and money. The FDA said it expects pooling will allow virus identification with fewer tests, which means more tests could be run at once, fewer testing supplies would be consumed and patients could likely receive results more quickly.

A primary indicator of success in the fight against COVID-19 is avoiding stress on critical care infrastructure and services (CCIS). However, CCIS will likely remain stressed until sustained herd immunity is built, either in due course or by vaccination on mass scale. There are also secondary considerations for success: mitigating economic damage; curbing the spread of misinformation, improving morale, and preserving a sense of control; building global trust for diplomacy, trade and travel; and restoring reliability and normalcy to day-to-day life, among others. We envision technology plays a pivotal role. Here, we focus on the effective use of readily available technology to improve the primary and secondary success criteria for the fight against SARS-CoV-2. In a multifaceted technology approach, in this Part I, we start with effective technology use for remote patient monitoring (RPM) of COVID-19 with the following objectives: 1. Deploying readily available technology for continuous real-time remote monitoring of patient vitals with the help of biosensors on a large scale.

It's impossible to contain covid-19 without knowing who's infected: until a safe and effective vaccine is widely available, stopping transmission is the name of the game. While testing capacity has increased, it's nowhere near what's needed to screen patients without symptoms, who account for nearly half of the virus's transmission. Our research points to a compelling opportunity for data science to effectively multiply today's testing capacity: if we combine machine learning with test pooling, large populations can be tested weekly or even daily, for as low as $3 to $5 per person per day. In other words, for the price per test of a cup of coffee, governments can safely reopen the economy and halt ongoing covid-19 transmission--all without building new labs and without new drugs or vaccines. Most people get tested for the coronavirus because they experienced symptoms, or came in close contact with someone who did.

Accuracy, precision, recall and other measures of AI efficacy are crucial but not sufficient. Will you use, trust, or make clinical decisions based on a technology that runs on "bad data" and are neither "clinically validated" nor "FDA approved"? From virtual assistants to technologies such as Apple Watch and IBM Watson, several applications of artificial intelligence (AI) have been established to augment health care systems, improve patient care, and assist care-providers. The growing involvement of technology giants such as Google, Apple, and IBM in health care technology have further enhanced the need to understand better the influence of AI on the health care industry. Many health care organizations are employing AI technologies to create new value in the industry.